LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma
A phase 2 trial of Infigratinib and Capmatinib in Melanoma, run by Pfizer, completed.
Overview
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma is a phase 2 interventional study registered as NCT02159066 by Pfizer, with 158 participants recorded, started 2014-07-23 and reaching its primary completion in 2023-01-10. Interventions recorded: LGX818, MEK162, LEE011, BGJ398, BKM120, INC280. Conditions recorded: Melanoma.
Linked to the drug Infigratinib because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialBGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer
Shares Infigratinib and the tag pipeline.
- TrialA Phase 2 Study of BGJ398 in Patients With Recurrent GBM
Shares Infigratinib and the tag pipeline.
- TrialA Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
Shares Capmatinib and the tag pipeline.
- TrialStudy to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
Shares Capmatinib and the tag pipeline.
- TrialA Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Shares Pfizer (incl. Seagen) and the tag pipeline.
- TrialA Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Shares Pfizer (incl. Seagen) and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Melanoma and the tag pipeline.
- TrialLong Term Study With B2036-PEG
Shares Pfizer (incl. Seagen) and the tag pipeline.